ARTICLE
19 October 2023

Tele-Prescribing Flexibilities Extended Again In Second Temporary Rule

SM
Sheppard Mullin Richter & Hampton

Contributor

Sheppard Mullin is a full service Global 100 firm with over 1,000 attorneys in 16 offices located in the United States, Europe and Asia. Since 1927, companies have turned to Sheppard Mullin to handle corporate and technology matters, high stakes litigation and complex financial transactions. In the US, the firm’s clients include more than half of the Fortune 100.
This month, the Drug Enforcement Administration ("DEA"), in conjunction with the Substance Abuse and Mental Health Services Administration ("SAMHSA"), issued a Second Temporary Rule...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

This month, the Drug Enforcement Administration ("DEA"), in conjunction with the Substance Abuse and Mental Health Services Administration ("SAMHSA"), issued a Second Temporary Rule further extending the telemedicine waivers of the Ryan Haight Act ("RHA") promulgated during the COVID-19 Public Health Emergency ("PHE") from November 11, 2023 until December 31, 2024. Under the Second Temporary Rule, practitioners may continue to prescribe schedule II-V controlled medications via telemedicine for new and existing patients without conducting a prior in-person medical evaluation through 2024.

As described in a previous update, the DEA proposed a rule in March 2023 to extend some flexibilities while making permanent certain scenarios in which a practitioner could prescribe controlled substances without a prior in-person evaluation. On May 10, 2023, the DEA in conjunction with SAMHSA issued the First Temporary Rule which (1) extended the full set of RHA waivers promulgated during the PHE until November 11, 2023 and (2) extended the telemedicine flexibilities until November 11, 2024 for patient-practitioner telemedicine relationships established on or before November 11, 2023, as explained in an earlier post. In September 2023, the DEA hosted Telemedicine Listening Sessions to obtain additional industry and stakeholder input.

This Second Temporary Rule extends the current flexibilities for prescribing controlled medications via telemedicine for all practitioner-patient relationships (not just those established on or before November 11, 2023) until the end of 2024. Some concerns and reasons noted by the DEA for extending the telemedicine flexibilities include:

  • Reductions in access to care for patients who may not have an established practitioner-patient relationship;
  • Practitioner backlogs for providing in-person medical evaluations; and
  • Urgent public health needs for certain controlled medications.

Sheppard Mullin will continue to monitor developments and provide updates as they arise. Providers with questions or seeking counsel can contact any member of ourHealthcare Teamfor assistance.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More